Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of “Hold” from Analysts

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) have received a consensus rating of “Hold” from the eleven research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $25.70.

A number of equities research analysts have recently weighed in on EYPT shares. Weiss Ratings raised shares of Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 1st. Wall Street Zen upgraded Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 22nd. Jefferies Financial Group lowered their price target on Eyepoint Pharmaceuticals to $8.00 and set a “buy” rating for the company in a research report on Monday, August 17th. Chardan Capital downgraded Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $5.00 price target on the stock. in a research note on Tuesday, August 18th. Finally, HC Wainwright reissued a “neutral” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday, August 18th.

Eyepoint Pharmaceuticals Stock Down 2.1%

Shares of Eyepoint Pharmaceuticals stock opened at $4.25 on Friday. The firm has a market capitalization of $366.39 million, a P/E ratio of -1.14 and a beta of 1.63. The company has a 50 day moving average price of $10.03 and a 200 day moving average price of $12.50. Eyepoint Pharmaceuticals has a 52 week low of $3.95 and a 52 week high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%.The company had revenue of $0.51 million during the quarter, compared to analyst estimates of $0.45 million. As a group, research analysts anticipate that Eyepoint Pharmaceuticals will post -3.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. KBC Group NV purchased a new stake in shares of Eyepoint Pharmaceuticals in the 1st quarter valued at $29,000. California State Teachers Retirement System raised its holdings in shares of Eyepoint Pharmaceuticals by 20.6% during the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after purchasing an additional 794 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new position in shares of Eyepoint Pharmaceuticals during the second quarter worth $72,000. Russell Investments Group Ltd. acquired a new position in Eyepoint Pharmaceuticals during the third quarter valued at $76,000. Finally, Persistent Asset Partners Ltd acquired a new position in Eyepoint Pharmaceuticals during the fourth quarter valued at $98,000. Institutional investors and hedge funds own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.